Summit Therapeutics Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2019 | $-35.1M | $-21.0M | $157.0K | $845.0K |
| FY2020 | $-48.1M | $-48.5M | $421.0K | $1.8M |
| FY2021 | $-72.6M | $-72.9M | $306.0K | $12.8M |
| FY2022 | $-41.6M | $-42.2M | $624.0K | $11.9M |
| FY2023 | $-76.8M | $-76.9M | $128.0K | $14.1M |
| FY2024 | $-142.1M | $-142.2M | $139.0K | $51.0M |
| FY2025 | $-322.9M | $-323.6M | $657.0K | $732.4M |